TNYA
Tenaya Therapeutics, Inc. NASDAQ Listed Jul 30, 2021$0.85
After hrs
$1.00
-0.01%
Mkt Cap $141.3M
52w Low $0.36
24.5% of range
52w High $2.35
50d MA $0.73
200d MA $1.02
P/E (TTM)
-1.2x
EV/EBITDA
-0.2x
P/B
0.9x
Debt/Equity
0.1x
ROE
-73.5%
P/FCF
-1.6x
RSI (14)
—
ATR (14)
—
Beta
3.00
50d MA
$0.73
200d MA
$1.02
Avg Volume
4.5M
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
CIK (SEC)
Phone
650 825 6900
171 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.13 | -0.12 | +7.7% | 0.86 | -1.0% | +4.0% | -0.7% | -0.2% | -0.2% | -4.2% | — |
| Nov 10, 2025 | AMC | -0.15 | -0.12 | +20.0% | 1.43 | +0.0% | -0.7% | +7.7% | -4.2% | -7.0% | -11.9% | — |
| Aug 6, 2025 | AMC | -0.20 | -0.14 | +30.0% | 0.67 | +0.8% | -1.7% | -0.8% | +1.0% | +12.2% | +27.6% | — |
| May 7, 2025 | AMC | -0.18 | -0.24 | -33.3% | 0.45 | +1.1% | -2.1% | -8.0% | -8.6% | -12.3% | -13.8% | — |
| Mar 10, 2025 | AMC | -0.31 | -0.28 | +9.7% | 0.51 | +2.4% | +6.8% | +18.7% | +32.5% | +38.2% | +44.4% | — |
| Nov 6, 2024 | AMC | -0.37 | -0.30 | +18.9% | 2.23 | +4.9% | +12.1% | +23.8% | +15.2% | -0.9% | -6.3% | — |
| Aug 8, 2024 | AMC | -0.40 | -0.34 | +15.0% | 2.68 | +1.5% | -1.1% | +1.5% | +13.8% | +5.6% | +11.9% | — |
| May 14, 2024 | AMC | -0.43 | -0.40 | +7.0% | 4.40 | +4.3% | -3.4% | -3.4% | +5.9% | -3.4% | -5.0% | — |
| Mar 18, 2024 | AMC | -0.45 | -0.40 | +11.1% | 4.82 | -0.8% | -6.0% | +1.7% | -0.8% | -2.1% | +0.8% | — |
| Nov 8, 2023 | AMC | -0.47 | -0.39 | +17.0% | 1.96 | +4.6% | -3.6% | -5.1% | -6.1% | -1.5% | -7.1% | — |
| Aug 9, 2023 | AMC | -0.51 | -0.45 | +11.8% | 4.18 | +1.4% | +5.5% | +5.7% | -1.7% | -6.5% | -8.1% | — |
| May 10, 2023 | AMC | -0.60 | -0.43 | +28.3% | 6.80 | +2.6% | +7.6% | -0.4% | +2.9% | -1.0% | +5.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.0% | +4.0% | -0.7% | -0.2% | -0.2% | -4.2% |
| Dec 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.67 | $0.70 | +4.7% | +0.1% | +5.0% | +13.5% | +5.4% | +11.7% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $1.36 | $1.05 | -22.8% | -37.5% | -41.4% | -43.8% | -51.0% | -50.9% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.05 | -22.8% | -37.5% | -41.4% | -43.8% | -51.0% | -50.9% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $1.28 | $1.20 | -6.2% | +11.7% | +10.9% | +20.3% | +7.0% | +3.9% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.12 | -0.9% | -4.4% | +4.4% | +9.7% | +19.5% | +23.9% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.11 | +2.8% | +1.9% | +4.6% | +4.6% | +0.0% | +9.3% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +0.8% | -1.7% | -0.8% | +1.0% | +12.2% | +27.6% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $0.44 | $0.45 | +2.1% | -6.1% | -6.7% | -10.5% | -12.0% | -0.7% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.48 | +4.8% | +6.6% | +5.0% | +4.9% | +3.1% | +10.7% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.64 | $0.64 | +0.1% | -11.3% | -15.3% | -11.9% | -19.1% | -22.4% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.60 | $0.63 | +4.3% | +11.6% | +16.4% | +21.6% | +13.8% | +16.2% |
| Mar 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $0.54 | $0.57 | +5.0% | +11.2% | +24.1% | +29.4% | +35.2% | +26.5% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.54 | $0.57 | +5.0% | +11.2% | +24.1% | +29.4% | +35.2% | +26.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.51 | $0.52 | +2.4% | +6.8% | +18.7% | +32.5% | +38.2% | +44.4% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.04 | -1.9% | -0.9% | -2.8% | -1.9% | -5.7% | -9.0% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.50 | $1.55 | +3.3% | -4.7% | -2.0% | -7.3% | -6.7% | -13.3% |
| Dec 18 | Chardan Capital | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -12.8% | +0.0% | +18.4% | +12.8% | +17.7% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -12.8% | +0.0% | +18.4% | +12.8% | +17.7% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.96 | $3.09 | +4.4% | +11.1% | +11.1% | +20.6% | +20.9% | +16.9% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.45 | +2.9% | +24.4% | +38.2% | +38.2% | +50.0% | +50.4% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.23 | $2.34 | +4.9% | +12.1% | +23.8% | +15.2% | -0.9% | -6.3% |
| Oct 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.15 | $2.21 | +2.8% | -5.1% | -10.7% | -11.2% | -13.0% | -14.9% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.21 | +2.8% | -5.1% | -10.7% | -11.2% | -13.0% | -14.9% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.92 | $2.88 | -1.4% | +2.1% | +2.7% | +5.1% | +19.9% | +20.2% |
| May 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.25 | $4.25 | +0.0% | +0.0% | +9.6% | +0.0% | -1.6% | +4.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.59 | +4.3% | -3.4% | -3.4% | +5.9% | -3.4% | -5.0% |
| Mar 21 | Chardan Capital | Maintains | Buy → Buy | — | $4.90 | $4.99 | +1.8% | -2.4% | -3.7% | -0.8% | -1.4% | +5.3% |
| Mar 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.53 | $4.52 | -0.2% | +8.2% | +5.5% | +4.2% | +7.3% | +6.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.78 | -0.8% | -6.0% | +1.7% | -0.8% | -2.1% | +0.8% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.49 | -3.1% | -0.8% | -0.2% | -6.2% | -11.7% | -10.9% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $4.42 | $4.53 | +2.5% | -7.0% | -11.5% | -13.1% | -13.6% | -12.0% |
| Aug 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.41 | $4.36 | -1.1% | +0.2% | -6.8% | -11.3% | -12.9% | -13.4% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.24 | +1.4% | +5.5% | +5.7% | -1.7% | -6.5% | -8.1% |
| Aug 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.18 | $4.24 | +1.4% | +5.5% | +5.7% | -1.7% | -6.5% | -8.1% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.32 | $7.54 | +3.0% | -7.5% | -4.4% | -8.1% | -2.3% | -1.4% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.98 | +2.6% | +7.6% | -0.4% | +2.9% | -1.0% | +5.1% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.34 | $3.15 | -5.7% | -12.6% | -21.9% | -14.7% | -21.6% | -21.4% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.34 | $3.15 | -5.7% | -12.6% | -21.9% | -14.7% | -21.6% | -21.4% |
| Jan 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.83 | $2.93 | +3.5% | +13.8% | +14.5% | +10.2% | +20.8% | +19.1% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $2.04 | $1.95 | -4.4% | +30.9% | +46.1% | +43.6% | +56.4% | +22.5% |
| Nov 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.92 | $2.01 | +4.7% | -5.2% | -0.5% | +6.2% | +39.1% | +55.2% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.49 | $5.63 | +2.6% | -0.5% | +2.2% | +4.4% | -3.5% | -8.4% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.38 | $5.90 | +9.7% | +1.1% | +1.1% | +0.7% | +10.6% | +15.4% |
| May 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.00 | $7.27 | +3.9% | +3.3% | -7.3% | -19.7% | -5.0% | -8.0% |
| Aug 24 | Cowen & Co. | Maintains | Outperform → Outperform | — | $23.35 | $23.80 | +1.9% | +2.5% | -4.3% | +0.6% | +14.2% | +10.4% |
| Aug 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.35 | $23.80 | +1.9% | +2.5% | -4.3% | +0.6% | +14.2% | +10.4% |
| Aug 24 | Chardan Capital | Maintains | Buy → Buy | — | $23.35 | $23.80 | +1.9% | +2.5% | -4.3% | +0.6% | +14.2% | +10.4% |
| Aug 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.35 | $23.80 | +1.9% | +2.5% | -4.3% | +0.6% | +14.2% | +10.4% |
No insider trades available.
8-K
Unknown — 8-K Filing
Tenaya Therapeutics (TNYA) is advancing its cardiac disease pipeline with positive momentum, suggesting potential near-term clinical catalysts that could justify its clinical-stage valuation if development programs succeed.
Mar 11
8-K · 1.01
!! High
Tenaya Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Tenaya Therapeutics secured a $10 million collaboration agreement with Alnylam Pharmaceuticals to develop RNA-based therapeutics, providing funding and potential revenue expansion for the smaller biotech firm.
Mar 5
Data updated apr 27, 2026 5:14am
· Source: massive.com